Phio Pharmaceuticals Corp (PHIO)

0.405
-0.005(-1.24%)
After Hours
0.391
0.000(0.102%)
- Real-time Data
  • Volume:
    26,853
  • Day's Range:
    0.390 - 0.420
  • 52 wk Range:
    0.390 - 2.420
Trading near 52-week Low

Phio Pharma has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

PHIO Overview

Prev. Close
0.41
Day's Range
0.39-0.42
Revenue
-
Open
0.39
52 wk Range
0.39-2.42
EPS
-0.897
Volume
26,853
Market Cap
5.53M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
69,830
P/E Ratio
-0.446
Beta
1.44
1-Year Change
-71.49%
Shares Outstanding
13,667,973
Next Earnings Date
Mar 30, 2023
What is your sentiment on Phio Pharma?
or
Market is currently closed. Voting is open during market hours.

Phio Pharmaceuticals Corp News

Phio Pharmaceuticals Corp Analysis

Phio Pharmaceuticals Corp Company Profile

Phio Pharmaceuticals Corp Company Profile

Employees
12

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Read More

Analyst Price Target

Average6.000 (+1381.48% Upside)
High6
Low6
Price0.405
No. of Analysts1
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • I took an impressive position here at 0.66 . Cancer game , I think soon there will be a run to the northern latitudes .
    0
    • PHIO Sept 16-21 ESMO Abstract Title says it all -> "persistent immunity" & "complete resolution of tumors" (eg 100% tumor elimination & lasting cancer immunity) can't get any better than that. Truly the Market hates PHIO/RXII because of the 'cloud' of 4 R/S 1,000:1 Otherwise PHIO PPS would've exploded. Only other explanation is that the investing public can't read or comprehend the impact of a cure for cancer.
      2
      • Nice move so far today
        0
        • THIS IS GOING TO 6
          0
          • 123 boom
            0
            • Target 10$
              0
              • $5.75
                0
                • Why such thebig fump
                  0
              • going up
                0
                • is this going to keep going up or dip
                  0
                  • did they already have earnings call?
                    0